PubRank

Keith A Baggerly

Author PubWeight™ 69.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics 2005 4.26
2 Steps toward mapping the human vasculature by phage display. Nat Med 2002 3.82
3 Non-parametric quantification of protein lysate arrays. Bioinformatics 2007 3.18
4 Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005 2.98
5 Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004 2.96
6 Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics 2005 2.81
7 Microarrays: retracing steps. Nat Med 2007 2.39
8 Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013 2.30
9 The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 2005 2.08
10 Bayesian analysis of mass spectrometry proteomic data using wavelet-based functional mixed models. Biometrics 2007 2.01
11 Serum proteomics profiling--a young technology begins to mature. Nat Biotechnol 2005 1.98
12 Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. J Clin Oncol 2008 1.96
13 Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003 1.88
14 Variable slope normalization of reverse phase protein arrays. Bioinformatics 2009 1.66
15 Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006 1.63
16 Understanding the characteristics of mass spectrometry data through the use of simulation. Cancer Inform 2005 1.52
17 Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 2011 1.33
18 Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 2009 1.30
19 Bayesian shrinkage estimation of the relative abundance of mRNA transcripts using SAGE. Biometrics 2003 1.28
20 Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS One 2009 1.27
21 Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat 2009 1.25
22 Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genomics 2008 1.25
23 Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain 2009 1.22
24 Identifying and quantifying sources of variation in microarray data using high-density cDNA membrane arrays. J Comput Biol 2002 1.17
25 Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 2012 1.14
26 PrepMS: TOF MS data graphical preprocessing tool. Bioinformatics 2006 1.13
27 Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004 1.12
28 Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst 2011 1.08
29 Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. J Proteome Res 2010 1.01
30 Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots. Cancer Inform 2012 1.00
31 Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer 2010 0.97
32 Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. Acta Neuropathol 2010 0.94
33 Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res 2014 0.94
34 Independent validation of a model using cell line chemosensitivity to predict response to therapy. J Natl Cancer Inst 2013 0.92
35 Molecular signatures of metastasis in head and neck cancer. Head Neck 2008 0.89
36 Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures. Proteome Sci 2012 0.88
37 Reproducibility of SELDI Spectra Across Time and Laboratories. Cancer Inform 2011 0.87
38 Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res 2013 0.86
39 Altered MEF2 isoforms in myotonic dystrophy and other neuromuscular disorders. Muscle Nerve 2010 0.85
40 Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol 2012 0.83
41 Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res 2013 0.83
42 Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther 2013 0.80
43 Statistical contributions to proteomic research. Methods Mol Biol 2010 0.77
44 Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy. Mol Imaging Biol 2013 0.77
45 Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. Rapid Commun Mass Spectrom 2005 0.76
46 Blasted cell line names. Cancer Inform 2010 0.75